Evidence map›Paper›PMID 40095199›Full record

ArticleJournal of cardiovascular translational research2025

PLK1 Downregulation Attenuates ET-1-Induced Cardiomyocyte Hypertrophy by Suppressing the ERK1/2 Pathway.

Jie Ding, Anqi Yang, Liping Zhou, Fulei Zhang, Huixing Zhou, Yuemei Zhang, Yan Wang, Yi Liu, Dandan Liang, Yuanyuan Liu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jie DingDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Anqi YangDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Liping ZhouDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Fulei ZhangDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Huixing ZhouDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Yuemei ZhangDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Yan WangJinzhou Medical University, Jinzhou, 121000, China.
Yi LiuDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Dandan LiangDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Yuanyuan LiuJinzhou Medical University, Jinzhou, 121000, China. liuyuanyuan201310@163.com.
Yahan WuDepartment of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China. wuyahan_qirmai@163.com.ORCID 0009-0007-5743-8512

Funding

China Postdoctoral Science Foundation 2022M722413China Postdoctoral Science Foundation 2022M722417Science and Technology Commission of Shanghai Municipality 22YF1436500Science and Technology Commission of Shanghai Municipality 23YF1434900Shanghai Municipal Education Commission 21CGA27Shanghai Pudong New Area Health Commission PWYgf2021-01
6 · The paper itself

Abstract

Cardiomyocyte hypertrophy is a key remodeling response to cardiac stress and an independent risk factor for heart failure. However, the molecular mechanism of cardiomyocyte hypertrophy is not yet fully understood. We here found Polo-like kinase 1 (PLK1) was crucial in regulating endothelin-1 (ET-1)-induced cardiomyocyte hypertrophy. Notably, PLK1 expression was significantly elevated in ET-1-induced hypertrophic cardiomyocytes and pressure overload-induced hypertrophic cardiac tissue. Knocking down Plk1 reduced the cell size of hypertrophic cardiomyocytes and suppressed the expression of hypertrophic markers, including ANP, BNP and β-MHC. The PLK1 inhibitor BI2536 had similar effects on hypertrophic cardiomyocytes. Mechanistically, the ERK1/2 pathway was identified as the key downstream pathway mediating the effects of PLK1 on ET-1-induced cardiomyocyte hypertrophy. Finally, the deficiency of PLK1 attenuated the hypertrophy of hiPSC-CMs. In summary, our study revealed that PLK1 regulates ET-1-induced cardiomyocyte hypertrophy through the ERK1/2 pathway, providing insights into the pathogenesis and potential therapies for pathological cardiac hypertrophy.

Indexed as

CardiomegalyCell Cycle ProteinsEndothelin-1MAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Myocytes, CardiacProtein Serine-Threonine KinasesProto-Oncogene ProteinsAnimalsCells, CulturedDisease Models, AnimalDown-RegulationHumansMaleMice, Inbred C57BLCell Cycle ProteinsEndothelin-1Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Polo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsCardiomyocyte HypertrophyEndothelin-1ERK1/2hiPSC-CMsPLK1

Identifiers

PMID40095199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.